Aperiam Bio

Executive Summary

Aperiam Bio is a San Francisco-based biotechnology company leveraging proprietary computer vision algorithms to engineer 'hyperfolding' protein variants. The platform identifies stabilizing mutations that can yield up to tenfold improvements in expression, solubility, and specific activity compared to wild-type proteins. Founded in 2021, the company applies its technology across three verticals: technical reagents (e.g., enzymes for diagnostics), cosmetics (active ingredients), and pulmonary biologics (inhaled therapeutics). By enhancing protein stability and manufacturability, Aperiam aims to reduce production costs and enable novel applications that were previously constrained by poor protein behavior. The company's hyperfolding approach addresses a critical bottleneck in protein engineering, offering a computational-first method that accelerates development timelines. Initial traction appears strongest in the technical reagents and cosmetics markets, where faster iteration and improved performance are highly valued. In pulmonary biologics, the platform could enable better formulation stability and delivery. Aperiam Bio is positioned to capture value across multiple industries, though it remains at an early stage with limited public disclosure. The convergence of AI-driven protein design and growing demand for sustainable, high-performance proteins presents a significant opportunity for the company to scale.

Upcoming Catalysts (preview)

• Q4 2026Series A financing round75% success
• Q1 2027First commercial partnership in technical reagents60% success
• Q2 2027Preclinical data readout for pulmonary biologic lead candidate50% success